HealthyPhase 1NCT02187575
Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers
A Phase 1 study testing UHAC 62 XX tablet and UHAC 62 XX capsule in people with Healthy, run by Boehringer Ingelheim.
Trial summary
Study to investigate the bioequivalence between 10 mg tablets (test drug) and 10 mg capsules (reference drug) of meloxicam (UHAC 62 XX) after 7-day administration. Read more about this study
- Who is it for?
- Ages 20 to 35 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- UHAC 62 XX tablet and UHAC 62 XX capsule
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- No sites listed yet
- Study dates
- Jul 2002to Sep 2002
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 35 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age >= 20 and <= 35 years
- Weight: Body Mass Index >= 18.5 and < 25
- Subjects who are judged by the investigator to be appropriate as the subjects of the study based on results of screening test
- Subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent
Who cannot join
- History of gastrointestinal ulcer or surgery of gastrointestinal tract (except appendectomy)
- History of hypersensitivity to UHAC 62 XX and/or salicylate (aspirin etc.) and/or Non-steroidal anti-inflammatory drugs (NSAIDs)
- History of aspirin induced asthma (bronchial asthma induced by NSAIDs)
- History of bleeding tendency
- History of alcohol or drug abuse
- Participation to another trial with an investigational drug within 4 months prior to the trial
Show all 14Show fewer
- Whole blood donation more than 400 ml within 3 months prior to the trial
- Whole blood donation more than 100 ml within 1 month prior to the trial
- Donation of constituent of blood of more than 400 ml within 1 month prior to the trial
- Any medication which might influence the results of the trial within 10 days prior to the trial
- Excessive physical activities within 7 days prior to the trial
- Alcohol drinking within 3 days prior to the trial
- History of orthostatic hypotension, fainting spells or blackouts
- Other than above, those who are judged by the investigator to be inappropriate as the subjects of the study
About this study
Official title: Bioequivalence Study of UHAC62XX 10 mg Tablets Compared With 10 mg Capsules Following Multiple Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)
Study to investigate the bioequivalence between 10 mg tablets (test drug) and 10 mg capsules (reference drug) of meloxicam (UHAC 62 XX) after 7-day administration.
- Conditions
- Healthy
- Being tested
- UHAC 62 XX tablet, UHAC 62 XX capsule
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
UHAC 62 XX tabletDrug
UHAC 62 XX capsuleDrug
| Study group | Role | What they receive |
|---|---|---|
| UHAC 62 XX tablet | Experimental | Not described Receives: Drug: UHAC 62 XX tablet |
| UHAC 62 XX capsule | Active comparator | Not described Receives: Drug: UHAC 62 XX capsule |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cmax (maximum observed concentration of the analyte in plasma)
Measured: up to day 8
AUC 0-τ (Area under the concentration time curve in plasma from zero time to 24 hours after 7-day administration)
Measured: up to day 8
Secondary outcomes (5)
Tmax (Time to reach Cmax)
Measured: up to day 8
T1/2 (Terminal half-life in plasma)
Measured: up to day 8
MRT 0-τ (Mean residence time in the body after 7-day administration)
Measured: up to day 8
Cτ (Concentration of the analyte in plasma 24 hours after 7-day administration)
Measured: up to day 8
Number of patients with adverse events
Measured: up to 20 days after final administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2014 (estimated)
- Study startJul 2002
- Primary completionSep 2002
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02187575
- Sponsor's protocol ID
- 107.259
- Status last verified
- Jul 2014
- First submitted
- 10 Jul 2014
- Last updated
- 14 Jul 2014
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioequivalence Study of UHAC62XX 10 mg Tablets Compared With 10 mg Capsules Following Multiple Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)
- ClinicalTrials.gov ID
- NCT02187575
- Acronym / sponsor ID
- 107.259
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Jul 2002
- Primary completion
- Sep 2002 (actual)
- First posted
- 11 Jul 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study to investigate the bioequivalence between 10 mg tablets (test drug) and 10 mg capsules (reference drug) of meloxicam (UHAC 62 XX) after 7-day administration.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| UHAC 62 XX tablet | Experimental | Drug: UHAC 62 XX tablet |
| UHAC 62 XX capsule | Active comparator | Drug: UHAC 62 XX capsule |
Who may qualify
- Ages
- 20 to 35 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (4 listed)
- Age >= 20 and <= 35 years
- Weight: Body Mass Index >= 18.5 and < 25
- Subjects who are judged by the investigator to be appropriate as the subjects of the study based on results of screening test
- Subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent
Key exclusion criteria (14 listed)
- History of gastrointestinal ulcer or surgery of gastrointestinal tract (except appendectomy)
- History of hypersensitivity to UHAC 62 XX and/or salicylate (aspirin etc.) and/or Non-steroidal anti-inflammatory drugs (NSAIDs)
- History of aspirin induced asthma (bronchial asthma induced by NSAIDs)
- History of bleeding tendency
- History of alcohol or drug abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| UHAC 62 XX tablet | Drug | UHAC 62 XX tablet |
| UHAC 62 XX capsule | Drug | UHAC 62 XX capsule |
Primary outcome
Cmax (maximum observed concentration of the analyte in plasma)
Time frame: up to day 8
AUC 0-τ (Area under the concentration time curve in plasma from zero time to 24 hours after 7-day administration)
Time frame: up to day 8
5 secondary outcomes
Tmax (Time to reach Cmax)
Time frame: up to day 8
T1/2 (Terminal half-life in plasma)
Time frame: up to day 8
MRT 0-τ (Mean residence time in the body after 7-day administration)
Time frame: up to day 8
Cτ (Concentration of the analyte in plasma 24 hours after 7-day administration)
Time frame: up to day 8
Number of patients with adverse events
Time frame: up to 20 days after final administration
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2014.
- Related InfoLink provided by the sponsor.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing UHAC 62 XX tablet and UHAC 62 XX capsule in people with Healthy, run by Boehringer Ingelheim.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2014. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cmax (maximum observed concentration of the analyte in plasma) (time frame: up to day 8). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2014.